Bruno Henrique Rala de Paula (Bruno de Paula, Elizabeth C Smyth, Elizabeth Smyth, Bruno H R de Paula)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 17

Top Topics

Locally Advanced

Positive Breast Cancer

Estrogen Receptor

Top Venues

Current oncology (Toronto, Ont.)

International journal of molecular sciences

Annals of translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Bruno Henrique Rala de Paula, Eliana Abdelhay, Carlos Augusto Moreira de Sousa, Susanne Crocamo Ventilari da Costa
Survival outcomes of Zo-NAnTAx: a five-year analysis of zoledronic acid added to a neoadjuvant regimen for HER2-positive breast cancer. Annals of translational medicine 12 (3) (2024)
Bruno Henrique Rala de Paula, Eliana Abdelhay, Carlos Augusto Moreira de Sousa, Susanne Crocamo Ventilari da Costa
Survival outcomes of Zo-NAnTAx: a five-year analysis of zoledronic acid added to a neoadjuvant regimen for HER2-positive breast cancer. Annals of translational medicine 12 (3) (2024)
Lucas Delmonico, José Bines, Cristina Moreira do Nascimento, Priscila Valverde Fernandes, Isabel de Souza Barbosa, Gabriel Brito Ribeiro, Bruno Henrique Rala de Paula, Rafaele Tavares Silvestre, Maria Helena Faria Ornellas, Gilda Alves, Claudia Lage
Nuclear and Cytoplasmic hTERT, Tumor-Infiltrating Lymphocytes, and Telomere Elongation Leukocytes Are Independent Factors in the Response to Neoadjuvant Treatment in HER2-Enriched Breast Cancer. Current oncology (Toronto, Ont.) 30 (4) (2023)
Lucas Delmonico, José Bines, Cristina Moreira do Nascimento, Priscila Valverde Fernandes, Isabel de Souza Barbosa, Gabriel Brito Ribeiro, Bruno Henrique Rala de Paula, Rafaele Tavares Silvestre, Maria Helena Faria Ornellas, Gilda Alves, Claudia Lage
Nuclear and Cytoplasmic hTERT, Tumor-Infiltrating Lymphocytes, and Telomere Elongation Leukocytes Are Independent Factors in the Response to Neoadjuvant Treatment in HER2-Enriched Breast Cancer. Current oncology (Toronto, Ont.) 30 (4) (2023)
Bruno Henrique Rala de Paula, Rosalind Kieran, Samantha Shui Yuan Koh, Susanne Crocamo Ventilari da Costa, Eliana Abdelhay, Daniel Muñoz-Espín
Targeting senescence as a therapeutic opportunity for triple-negative breast cancer. Molecular cancer therapeutics (2023)
Lucas Delmonico, José Bines, Cristina Moreira do Nascimento, Priscila Valverde Fernandes, Isabel de Souza Barbosa, Gabriel Brito Ribeiro, Bruno Henrique Rala de Paula, Rafaele Tavares Silvestre, Maria Helena Faria Ornellas, Gilda Alves, Claudia Lage
Nuclear and Cytoplasmic hTERT, Tumor-Infiltrating Lymphocytes, and Telomere Elongation Leukocytes Are Independent Factors in the Response to Neoadjuvant Treatment in HER2-Enriched Breast Cancer. Current oncology (Toronto, Ont.) 30 (4) (2023)
Susanne Crocamo Ventilari da Costa, Renata Binato, Everton Cruz Dos Santos, Bruno Henrique Rala de Paula, Eliana Abdelhay
Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer. International journal of molecular sciences 23 (24) (2022)
Bruno Henrique Rala de Paula, Susanne Crocamo, Jose Bines
Clinical considerations for estrogen receptor-negative/progesterone receptor-positive/HER2-negative (ER - PR + HER2 - ) breast cancer. Translational breast cancer research : a journal focusing on translational research in breast cancer 4 (2022)
Susanne Crocamo Ventilari da Costa, Renata Binato, Everton Cruz Dos Santos, Bruno Henrique Rala de Paula, Eliana Abdelhay
Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer. International journal of molecular sciences 23 (24) (2022)
Bruno Henrique Rala de Paula, Susanne Crocamo, Jose Bines
Clinical considerations for estrogen receptor-negative/progesterone receptor-positive/HER2-negative (ER - PR + HER2 - ) breast cancer. Translational breast cancer research : a journal focusing on translational research in breast cancer 4 (2022)
Gary J Doherty, Mehmet Goksu, Bruno Henrique Rala de Paula
Rethinking cancer clinical trials for COVID-19 and beyond. Nature cancer 1 (6) (2022)
Rosalind Kieran, Bruno Henrique Rala de Paula, Michael Hubank, Allanah Barker, Anna L Paterson, David Gilligan, Gary J Doherty
Response of NOTCH1-Activated Tracheal Adenoid Cystic Carcinoma to the Gamma Secretase Inhibitor Nirogacestat. JCO precision oncology 5 (2022)
Susanne Crocamo Ventilari da Costa, Renata Binato, Everton Cruz Dos Santos, Bruno Henrique Rala de Paula, Eliana Abdelhay
Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer. International journal of molecular sciences 23 (24) (2022)
Bruno De Paula, Bruno Henrique Rala de Paula
Personalising care in oesophageal cancer care with liquid biopsy. British journal of cancer 125 (8) (2021)
Thibaud Koessler, Maria Alsina, Dirk Arnold, Irit Ben-Aharon, Manfred P Lutz, Radka Obermannova, Mark Peeters, Francesco Sclafani, Bruno Henrique Rala de Paula, Juan W Valle, Anna Dorothea Wagner, Lucjan Wyrwicz, Elisa Fontana, Markus Moehler
Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group. British journal of cancer 125 (7) (2021)
Gary J Doherty, Mehmet Goksu, Bruno Henrique Rala de Paula
Rethinking cancer clinical trials for COVID-19 and beyond. Nature cancer (2020)
Jessé Lopes da Silva, Bruno Henrique Rala de Paula, Isabele Avila Small, Luiz Claudio Santos Thuler, Andréia Cristina de Melo
Sociodemographic, Clinical, and Pathological Factors Influencing Outcomes in Locally Advanced Triple Negative Breast Cancer: A Brazilian Cohort. Breast cancer : basic and clinical research 14 (2020)